Phosplatin Therapeutics has engaged in research and development activities with collaborators in thirteen countries.
Our relationships within the pharmaceutical industry, with U.S. and European universities, and with contract research organizations, cover Clinical Development, translational research activities, as well as manufacturing and analytical method development for PT-112, our lead agent in oncology therapeutics.
PT-112 is the subject of two approved IND applications with US FDA, and clinical trials in the UNited States and in Asia.
To learn more about the Ongoing U.S. Phase I study in solid tumors, please visit the link below:
To learn more about the U.S. Phase I / II Study in hematological malignancies, please visit the link below:
To learn more about the combination study of PT-112 in taiwan, please visit the separate link below:
More information will be forthcoming about development activities in hematological malignancies, and in combination studies with immune checkpoint inhibition.